Related Experiment Videos
[Clinical implications of trastuzumab]
Toshiaki Saeki1, Shigemitsu Takashima
1Department of Clinical Research & Surgery, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama 790-0007, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2003
Summary
Trastuzumab targets C-erbB-2 (HER2/neu) in breast cancer. Combination therapy with paclitaxel improves response rates but increases cardiac risks, necessitating careful patient selection for HER2-positive tumors.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Context:
- C-erbB-2 (HER2/neu) protein overexpression is a target in solid tumors.
- HER2/neu is a membrane-bound protein in the EGFR family.
- Trastuzumab is a monoclonal antibody targeting the extracellular domain of HER2/neu.
Purpose:
- To investigate the efficacy and safety of Trastuzumab in treating C-erbB-2 positive breast cancer.
- To evaluate the impact of combination therapy with paclitaxel.
- To identify patient subgroups likely to respond to Trastuzumab treatment.
Summary:
- Trastuzumab targets HER2/neu in breast cancer, with response rates around 15% as a single agent.
- Patients with ICH 2+/FISH positive or ICH 3+ tumors are potential good responders.
- Combination therapy with paclitaxel significantly increases response rates (>60%) and improves progression-free survival.
- Trastuzumab can cause severe congestive heart failure, especially when combined with anthracyclines.
Impact:
- Identifies HER2/neu as a viable therapeutic target in oncology.
- Demonstrates the benefit of targeted therapy and combination treatments in metastatic breast cancer.
- Highlights the critical need for cardiac monitoring due to potential Trastuzumab-induced cardiotoxicity.